Lasso Peptides and RiPPs: Threaded Topologies, Genome Mining and Extreme Stability Research

Some peptide scaffolds fold. Lasso peptides thread. That distinction sounds trivial until you try to unfold one with heat, acid, or a protease, and it simply refuses to come apart. This class of ribosomally synthesized and post-translationally modified peptides, or RiPPs, has become one of the more interesting corners of natural product research precisely because its stability seems almost disproportionate to its small size.

Genome mining has turned lasso peptide discovery from a slow, bioassay-driven hunt into something closer to a bioinformatics exercise, and the pace of new scaffold identification has accelerated accordingly over the past decade.

The Threaded Topology, Explained

A lasso peptide’s defining feature is a macrolactam ring, formed when the N-terminal amine of the first residue forms an isopeptide bond with the side-chain carboxylate of an internal Asp or Glu residue, typically at position 8 or 9. The C-terminal tail then threads through this ring and gets sterically trapped, usually by bulky residues flanking the ring that act as steric locks, sometimes reinforced by disulfide bonds in class I and III lasso peptides.

The result is a mechanically interlocked structure rather than a purely folded one. Researchers often describe it as similar to a lasso or a [1]rotaxane, and the comparison is more than decorative, it is topologically accurate. Microcin J25, one of the best-studied lasso peptides, has this threaded architecture confirmed by NMR and crystallography, and its ring-tail interlock is what gives it resistance to both thermal denaturation and enzymatic digestion.

Why Threading Confers Extreme Stability

Why does a threaded topology matter so much for stability research? Because proteolytic enzymes generally need an extended, accessible peptide backbone to dock into their active site, and a threaded ring-and-tail structure simply doesn’t present that geometry. Trypsin and chymotrypsin, which would chew through a linear peptide of comparable sequence in minutes, often show negligible activity against native lasso topologies even after extended incubation.

Thermal stability tells a similar story. Several lasso peptides retain their threaded conformation after exposure to temperatures exceeding 90°C, only unthreading under more forcing conditions or with targeted mutation of the steric lock residues. This is unusual for a peptide of only 15 to 24 residues, and it has made lasso scaffolds an attractive template for engineering protease-resistant peptide-drug conjugate candidates in early-stage design work.

Class Differences Worth Noting

Lasso peptides are typically grouped into four classes based on disulfide content and connectivity. Class I peptides carry two disulfide bonds, class II have none, class III carry a single disulfide bridging the ring and tail, and class IV peptides feature a single disulfide bond in a different connectivity pattern. Class II peptides, lacking disulfides entirely, rely purely on steric locking for their stability, which makes them a particularly clean system for studying threading mechanics in isolation.

Genome Mining Pipelines for Discovery

The biosynthetic gene cluster for a lasso peptide is compact and recognizable: a precursor peptide gene (A), a leader peptidase (B1), a RiPP recognition element, and a macrolactam synthetase (typically split into B2 and C functions, or fused). That genetic signature is distinctive enough to search for directly across sequenced bacterial genomes, which is exactly what tools like RODEO and various HMM-based scanning pipelines do.

Genome mining searches typically start by scanning for conserved cyclase domains, then work backward to identify adjacent precursor peptide sequences, applying core motif rules (a Gly or Cys at the ring-closing position, appropriate spacing to the Asp/Glu residue) to filter candidates. This approach has already pulled hundreds of putative lasso peptide gene clusters out of genomic databases, most from Actinobacteria and Proteobacteria, with only a fraction experimentally characterized so far. That gap between predicted and validated scaffolds represents a substantial reservoir for future structural and functional research.

• Precursor peptide gene identification via conserved leader sequences
• Macrolactam cyclase domain scanning (B2/C-type enzymes)
• Ring-forming residue spacing rules (Gly/Cys to Asp/Glu)
• Heterologous expression in engineered E. coli or Streptomyces hosts for validation

Biological Activities Under Investigation

Once produced and confirmed structurally, lasso peptides have shown a range of activities in research settings: RNA polymerase inhibition (microcin J25 blocks the secondary channel of bacterial RNA polymerase with reported nanomolar-range potency in enzymatic assays), enzyme inhibition against angiotensin-converting enzyme in the case of lariatins and siamycins, and antimicrobial activity against Gram-negative pathogens for several class II members. The mechanistic diversity across a structurally conserved scaffold is itself a point of interest, since it suggests the threaded fold is a stable chassis onto which quite different pharmacophores can be mounted via sequence variation in the loop and tail regions.

Research Outlook

Where does lasso peptide research go from here? Synthetic biology groups are already experimenting with engineered variants, swapping loop sequences to redirect target specificity while preserving the mechanically locked core, essentially using the topology as a stable delivery chassis for designed activity. Total synthesis routes for lasso peptides remain genuinely difficult given the interlocked geometry, which keeps heterologous biosynthesis as the dominant production strategy for now.

As sequencing databases keep expanding and genome mining tools grow more sensitive to divergent core motifs, expect the catalogue of characterized lasso peptides to keep climbing well past current numbers, with particular interest in scaffolds active against resistant bacterial targets and in engineered variants built for peptide-drug conjugate applications.

Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.